The French biotech company, C4Diagnostics®, developing innovative in vitro diagnostic tests in the field of infectious diseases, announces that it has raised € 2.3 million in its Series A funding round led by US private investor Andreï Polukhtin, with the participation of French fund CAAP Création and of its historical shareholders, including Région Sud Investissement (advised by Turenne Groupe) and R2V (managed by ACG Management).
